ABOUT US

Our Vision

Our vision is a world where no newborn suffers irreversible harm from life-saving care. We aim to lead in neonatal-focused innovative therapeutics, bridging research, clinical practice, and global access.

Our Mission

At CanVeer Biopharma, our mission is simple yet transformative:

CanVeer Biopharma’s mission is to advance breakthrough therapeutics that protect the most vulnerable patients, premature infants, by preventing and treating life-threatening respiratory diseases.

Through rigorous science and compassionate innovation, we strive to protect fragile lives, reduce long-term complications, and give every child the chance to thrive.

We aim to:
Deliver the first effective drug treatment for bronchopulmonary dysplasia (BPD).
Reduce the long-term health and economic burden of premature birth.
Bring innovative neonatal therapies from scientific discovery to clinical reality.
Ensure every prematurely born infant has a safer, healthier start to life.

Our commitment is grounded in science, compassion, and the belief that cutting-edge research should meaningfully improve patient outcomes.

Leadership

Sherif Louis, PhD, MBA

Chief Executive Officer

Dr. Louis is an accomplished scientist and business leader with over 20 years of executive experience in biotech industry development, commercialization, and business management. Dr. Louis has a proven track record in bridging research and industry, driving innovative breakthrough discoveries to the clinic. He contributed to the advancement of several biotech healthcare startups, most notably Telo Genomics where he held several executive roles, advancing the Company’s technology from Academia to the clinic. Dr. Louis is expert in curating sustainable strategic partnerships with world leading industry players including Novartis, J&J, the Mayo Clinic, Dana Farber Institute, the Cleveland Clinic among several others. Dr. Louis holds a PhD in Biomedical Sciences and MSc in Biochemistry from the University of Manitoba, complemented by a PMP certification.

Dr. Behzad Yeganeh, PhD.

Chief Scientific Officer & Inventor

Dr. Yeganeh is a biomedical scientist with deep expertise in neonatal lung disease, cell therapy, and drug development. Dr. Yeganeh have over 20 years of experience conducting groundbreaking research in several top tier research institutions including Sickids Research Institute, Toronto, Canada, Children Hospital Research Institute Manitoba (CHRIM), Winnipeg, Canada, Children Hospital of Eastern Ontario Research Institute (CHEO RI), Ottawa, Canada. Dr. Yeganeh has authored 45+ peer- reviewed publications and is the principal inventor of several patents including the AlveoShield™ (Investigational New Drug), the newly patented therapeutic approach for preventing and treating BPD

Together, Dr. Louis and Dr. Yeganeh embody CanVeer’s blend of innovative research and entrepreneurial drive, positioning us at the forefront of neonatal pharmaceutical advancements.

CanVeer Advisory Board:

CanVeer Advisory Board is Chaired by Dr. Behzad Yeganeh and includes distinguished scientists and experts. CanVeer is working diligently to expand its roaster of Advisors of Subject Matter Experts in neonatal pediatrics, regulatory affairs, financing and corporate strategies

Dr. Martin Post, PhD

Dr. Post is a Professor at the University of Toronto and a Senior Scientist at the
SickKids Research Institute in Toronto. He leads a research group dedicated to lung
development, injury, and repair. His team has pioneered the generation of human
alveolar-like macrophages from stem cells as a potential cell therapy for lung
diseases, including respiratory syncytial virus (RSV) and bacterial infections
associated with cystic fibrosis, with the goal of mitigating disease severity and
progression.

Ali Hamraghani, PharmD, MSc.

Dr. Hamraghani is a pharmaceutical R&D specialist with extensive experience in research, development, and therapeutics formulation and manufacturing. Over his career, he has created several advanced drug formulations, developed analytical methods to global pharmacopeial standards, and successfully led the transfer of more than 18 pharmaceutical products to market. His expertise covers process validation, impurity profiling, stability testing, and bioequivalence studies. With a strong background in scaling up production and improving efficiency in GMP environments.

Dr. Robert Jankov, MD, PhD

Dr. Jankov is a distinguished pediatric and neonatologist Physician & Scientist. Dr. Jankov has over 30 years of experience conducting research in Australia and Canada to advance the treatment of chronic pulmonary vascular disease, which in neonate predominantly is the causal of bronchopulmonary dysplasia (BPD) and other developmental lung disorders. His research includes the cellular and molecular mechanisms of vascular remodeling, right- ventricular dysfunction, and nitric oxide unresponsiveness in pulmonary hypertension during early life.

Dr. Azadeh Yeganeh, PhD

Dr. Azadeh Yeganeh is a senior regulatory professional with extensive expertise in the regulatory review of non-clinical and clinical data, including pre-submission packages and regulatory risk assessments. As a Regulatory Advisor at Canveer, she provides science-based evaluations of data adequacy, identifies residual risks and gaps, and ensures alignment of development programs with regulatory expectations to support informed decision-making and compliant regulatory submissions.